Evidence map›Paper›PMID 23824712›Full record

ArticleAmerican journal of medical genetics. Part A2013

Risk terminology in biobanking and genetic research: what's in a name?

Gwendolyn P Quinn, Heide Castañeda, Tuya Pal, Janique L Rice, Cathy D Meade, Clement K Gwede

Abstract read
In one paragraph

Article in American journal of medical genetics. Part A, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gwendolyn P QuinnDivision of Cancer Prevention and Control, Moffitt Cancer Center, Tampa, FL 33612, USA. gwen.quinn@moffitt.org
Heide Castañeda
Tuya Pal
Janique L Rice
Cathy D Meade
Clement K Gwede

Funding

Training ProgramU54CA153509 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI GWEDE, CLEMENT K., MEADE, CATHY D. · 2010 to 2015
$4.8M
NCI NIH HHS 3U54CA153509-02S4NCI NIH HHS U54 CA153509
6 · The paper itself

Abstract

It is well established that the general public has varying interpretations of the term "risk" and the qualifiers associated with it, such as low, moderate, or high. What is less well known is how definition and application of this term impacts recruitment of individuals, particularly for biomedical and behavioral research designed to improve knowledge of and access to innovations in cancer genetics. This Commentary discusses the nomenclature used in bio-behavioral research and the potential for confusion due to divergent meanings of risk and its associated categorizations. We discuss both our experience with recruitment of familial cancer families for a study on perceptions of biobanking as well as lessons learned from published examples where divergent understanding of risk levels, genetic research processes, and interpretation of results between community members and researchers result in misunderstandings for both parties. Ultimately, a critical challenge remains to ensure that accurate and mutually relevant risk terms are used in recruiting research participants and providing genetic results. Achieving this goal requires that regulations, policy, education, and practice change in step with rapid discoveries in genetic research to reduce misinterpretations resulting from lack of common understanding and specificity in risk terminology.

Indexed as

Biological Specimen BanksGenetic ResearchNeoplasmsRisk AssessmentTerminology as TopicHealth CommunicationHumansbiobankingbioethicsethicsrisk communication

Identifiers

PMID23824712
PMCPMC3729791

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.